Chronic Kidney Disease Trial, Recruiting NCT07052539 Sponsor: University of Mississippi Medical Center Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT07052539
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Cohort 1: Healthy Participants

Who might be able to join this trial:

  • Adults between 18 and 75 years old
  • People with normal kidney function
  • People without heart failure
  • People with a body mass index (BMI) between 25 and 30 (considered overweight but not obese)

Who may not be able to join:

  • People with a long-term (chronic) illness
  • People whose kidneys are not filtering blood well enough (confirm with trial site)
  • People who are pregnant or breastfeeding
  • People who have had a skin or allergic reaction to iodine-based products or contrast dyes (a type of liquid sometimes used in medical scans)
  • People with low levels of red blood cells (confirm with trial site)
  • People who have been acutely unwell or hospitalised in the past 3 months
  • People who are unable to stop taking anti-inflammatory pain medications (such as ibuprofen or naproxen)
  • People with certain serious conditions, including multiple myeloma, amyloidosis, a type of adrenal gland tumour (pheochromocytoma), sickle cell disease, brain tumours that have spread, advanced kidney disease, liver problems, a severe bloodstream infection, or an overactive thyroid
  • People who currently use nicotine or recreational drugs, or who drink alcohol heavily on a regular basis

Cohort 2: Obese Participants without Heart Failure

Who might be able to join this trial:

  • Adults between 18 and 75 years old
  • People with adequate kidney function (confirm with trial site)
  • People with a BMI greater than 35 (considered severely obese)

Who may not be able to join:

  • People who have been diagnosed with heart failure
  • People with a long-term (chronic) illness
  • People whose kidneys are not filtering blood well enough (confirm with trial site)
  • People who are pregnant or breastfeeding
  • People who have had a skin or allergic reaction to iodine-based products or contrast dyes
  • People with low levels of red blood cells (confirm with trial site)
  • People who have been acutely unwell or hospitalised in the past 3 months
  • People who are unable to stop taking anti-inflammatory pain medications (such as ibuprofen or naproxen)
  • People with certain serious conditions, including multiple myeloma, amyloidosis, pheochromocytoma, sickle cell disease, brain tumours that have spread, advanced kidney disease, liver problems, a severe bloodstream infection, or an overactive thyroid
  • People who currently use nicotine or recreational drugs, or who drink alcohol heavily on a regular basis

Cohort 3: Obese Participants with a Specific Type of Heart Failure (HFpEF)

Who might be able to join this trial:

  • Adults between 18 and 75 years old
  • People with adequate kidney function (confirm with trial site)
  • People with a BMI greater than 35 (considered severely obese)
  • People who have been diagnosed with a specific type of heart failure called HFpEF, confirmed by heart scan results and a clinical scoring tool (confirm with trial site)

Who may not be able to join:

  • People whose heart failure symptoms are severe (classified as NYHA Class III or IV — meaning significant or severe limitations on physical activity)
  • People who have difficulty emptying their bladder fully
  • People with mobility difficulties
  • People who have previously had dialysis or a kidney transplant
  • People who have been acutely unwell or hospitalised in the past 3 months
  • People with a history of cancer, chemotherapy, or radiation therapy
  • People who are pregnant or breastfeeding
  • People who have had a skin or allergic reaction to contrast dyes
  • People with low levels of red blood cells (confirm with trial site)
  • People with certain serious conditions, including multiple myeloma, amyloidosis, pheochromocytoma, sickle cell disease, brain tumours that have spread, advanced kidney disease, liver problems, a severe bloodstream infection, or an overactive thyroid
  • People who are unable to stop taking anti-inflammatory pain medications (such as ibuprofen or naproxen)
  • People who currently use nicotine or recreational drugs, or who drink alcohol heavily on a regular basis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Marissa C Tio, MD, University of Mississippi Medical Center

Phone: 601-496-7834

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Mississippi Medical Center
Registry
ClinicalTrials.gov
Start date
22 July 2022
Est. completion
30 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in measured GFR; Change in urine sodium excretion

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov